Literature DB >> 19690093

Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study.

R Nandhagopal1, L Kuramoto, M Schulzer, E Mak, J Cragg, Chong S Lee, J McKenzie, S McCormick, A Samii, A Troiano, T J Ruth, V Sossi, R de la Fuente-Fernandez, Donald B Calne, A J Stoessl.   

Abstract

Parkinson's disease is a heterogeneous disorder with multiple factors contributing to disease initiation and progression. Using serial, multi-tracer positron emission tomography imaging, we studied a cohort of 78 subjects with sporadic Parkinson's disease to understand the disease course better. Subjects were scanned with radiotracers of presynaptic dopaminergic integrity at baseline and again after 4 and 8 years of follow-up. Non-linear multivariate regression analyses, using random effects, of the form BP(ND)(t) or K(occ)(t) = a*e((-)(bt)(-d)(A) + c, where BP(ND) = tracer binding potential (nondispaceable), K(OCC) = tracer uptake constant a, b, c and d are regression parameters, t is the symptom duration and A is the age at onset, were utilized to model the longitudinal progression of radiotracer binding/uptake. We found that the initial tracer binding/uptake was significantly different in anterior versus posterior striatal subregions, indicating that the degree of denervation at disease onset was different between regions. However, the relative rate of decline in tracer binding/uptake was similar between the striatal subregions. While an antero-posterior gradient of severity was maintained for dopamine synthesis, storage and reuptake, the asymmetry between the more and less affected striatum became less prominent over the disease course. Our study suggests that the mechanisms underlying Parkinson's disease initiation and progression are probably different. Whereas factors responsible for disease initiation affect striatal subregions differently, those factors contributing to disease progression affect all striatal subregions to a similar degree and may therefore reflect non-specific mechanisms such as oxidative stress, inflammation or excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690093     DOI: 10.1093/brain/awp209

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  78 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

Review 3.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

4.  Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease.

Authors:  Janey Prodoehl; Mathew Spraker; Daniel Corcos; Cynthia Comella; David Vaillancourt
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

Review 5.  Astrocytes in neurodegenerative disease.

Authors:  Hemali Phatnani; Tom Maniatis
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-15       Impact factor: 10.005

Review 6.  [Early recognition of Parkinson's disease. Objectifiable non-motor symptoms and biomarkers].

Authors:  B Mollenhauer; F Sixel-Döring; A Storch; C Schneider; R Hilker; E Kalbe
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

7.  Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.

Authors:  Jeffrey H Kordower; C Warren Olanow; Hemraj B Dodiya; Yaping Chu; Thomas G Beach; Charles H Adler; Glenda M Halliday; Raymond T Bartus
Journal:  Brain       Date:  2013-08       Impact factor: 13.501

Review 8.  Dopamine overdose hypothesis: evidence and clinical implications.

Authors:  David E Vaillancourt; Daniel Schonfeld; Youngbin Kwak; Nicolaas I Bohnen; Rachael Seidler
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

Review 9.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

10.  Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Authors:  Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.